shortli
epidem
etiolog
agent
sever
acut
respiratori
syndrom
sar
determin
sar
coronaviru
sarscov
drosten
et
al
ksiazek
et
al
kuiken
et
al
peiri
et
al
similar
virus
coronavirida
famili
sarscov
character
crownlik
outer
shell
compris
primarili
spike
glycoprotein
mediat
viral
entri
interact
host
cellular
receptor
li
et
al
along
group
previous
show
high
titer
neutral
antibodi
nab
primarili
direct
toward
receptorbind
domain
rbd
protein
chen
et
al
et
al
yi
et
al
thu
protein
rbd
serv
major
viral
target
vaccin
design
bukreyev
et
al
chen
et
al
yang
et
al
multipl
form
sar
vaccin
includ
dna
mva
independ
proven
effect
protect
anim
pathogen
sarscov
challeng
bisht
et
al
gao
et
al
yang
et
al
success
studi
result
minim
need
develop
regimen
sar
date
howev
remain
unknown
minim
level
nab
requir
achiev
steril
immun
human
recent
evid
better
protect
may
requir
suffici
amount
specif
nab
deme
et
al
liu
et
al
therefor
critic
explor
techniqu
maxim
level
nab
respons
vivo
evalu
strategi
use
variou
combin
dna
mva
determin
regimen
induc
highest
persist
level
nab
respons
aim
identifi
optim
vaccin
regimen
prevent
sarscov
infect
also
combat
tough
virus
includ
human
immunodefici
viru
type
one
gene
origin
obtain
sarscov
isol
hong
kong
genbank
access
number
zeng
et
al
base
viral
genom
sequenc
construct
codonoptim
fulllength
gene
use
synthet
overlap
oligonucleotid
zhang
et
al
optim
gene
clone
eukaryot
express
vector
control
cytomegaloviru
cmv
promot
invitrogen
carlsbad
ca
use
dna
vaccin
construct
mva
previous
describ
chen
et
al
fulllength
codonoptim
sar
gene
insert
recombin
vector
use
bd
adenox
express
system
bd
bioscienc
palo
alto
ca
briefli
fulllength
gene
clone
pdnrcmv
donor
vector
recombin
plpadenoxcmv
pac
idigest
recombin
adenovir
vector
transfect
atcc
supernat
collect
day
posttransfect
supernat
use
infect
larg
cultur
cell
largescal
product
recombin
adenoviru
purifi
use
two
success
cscl
gradient
first
gml
gml
second
gml
centrifug
spin
rpm
concentr
dialyz
phosphat
buffer
salin
pb
store
glycerol
six
eightweekold
femal
balbc
mice
charl
river
laboratori
immun
intramuscular
im
inject
dna
mva
dose
vaccin
dna
salin
tissu
cultur
infect
dose
mva
collect
blood
sampl
week
first
immun
four
week
prime
boost
sever
group
prime
mice
three
mice
per
group
dna
mva
accord
variou
regimen
mice
kill
blood
sampl
use
analysi
week
second
immun
new
zealand
white
rabbit
charl
river
laboratori
immun
im
inject
mva
three
rabbit
immun
mva
anoth
six
immun
day
four
week
later
three
mvasprim
anim
boost
dose
wherea
rest
receiv
mva
blood
sampl
collect
week
first
immun
week
second
immun
anim
experi
approv
conduct
laboratori
anim
research
center
rockefel
univers
pseudovirusbas
neutral
assay
establish
determin
humor
immun
respons
sarscov
chen
et
al
briefli
neutral
activ
heatinactiv
sera
min
determin
mix
ng
pseudoviru
dilut
serum
h
sarspseudoviru
gener
cotransfect
cell
two
plasmid
carri
optim
gene
backbon
respect
neutral
mixtur
combin
polybren
medium
ad
cell
per
well
cell
wash
pb
lyse
cell
cultur
lysi
reagent
promega
h
infect
luciferas
intens
measur
percentag
neutral
calcul
determin
nab
respons
variou
immun
construct
separ
dna
mva
vaccin
contain
fulllength
sarscov
gene
immun
three
group
balbc
mice
either
dna
nine
mice
mva
six
mice
six
mice
sera
collect
week
first
immun
sequenti
dilut
measur
level
nab
activ
sarspseudoviru
shown
fig
prime
elicit
highest
level
nab
sarspseudoviru
mva
induc
tenfold
lower
level
nab
dna
lowest
fig
therefor
live
vector
may
offer
advantag
induc
highest
level
nab
respons
one
immun
interestingli
initi
level
nab
prime
necessarili
predict
magnitud
secondari
respons
boost
four
week
first
immun
mice
boost
dna
mva
sera
collect
week
boost
sequenti
dilut
measur
level
nab
activ
sarspseudoviru
second
immun
boost
nab
respons
group
compar
regimen
effect
base
valu
found
dna
prime
dna
boost
dd
regimen
induc
lowest
level
nab
activ
fig
hand
prime
mva
boost
produc
highest
level
nab
tenfold
greater
dd
anim
fig
detect
rel
lower
level
nab
mice
prime
mva
dna
boost
mva
mm
dm
anim
fig
surprisingli
mice
prime
boost
either
mva
aa
show
level
dd
regimen
rest
fig
find
indic
import
heterolog
mva
prime
boost
regimen
induc
substanti
level
nab
respons
use
regimen
also
offer
advantag
overcom
problem
relat
vaccineinduc
immun
respons
live
viral
vector
determin
whether
find
mice
reproduc
differ
anim
speci
prime
nine
new
zealand
white
rabbit
either
six
rabbit
mva
three
rabbit
thirti
day
first
immun
measur
presenc
nab
sar
rabbit
serum
collect
serum
sequenti
dilut
analyz
neutral
activ
sarspseudoviru
six
rabbit
immun
measur
averag
greater
serum
dilut
fig
observ
significantli
greater
level
nab
rabbit
immun
rabbit
immun
mva
show
averag
fig
therefor
similar
mice
show
one
immun
induc
greater
antibodi
respons
use
rather
mva
viral
vector
vaccin
measur
nab
respons
prime
boost
rabbit
either
mva
three
rabbit
prime
boost
mva
wherea
remain
three
boost
anoth
inject
aa
three
rabbit
prime
mva
boost
two
week
second
inject
collect
serum
sampl
sequenti
dilut
measur
level
nab
activ
sarspseudoviru
rabbit
prime
boost
either
aa
mva
show
compar
level
nab
activ
fig
howev
rabbit
prime
mva
boost
observ
significantli
higher
level
nab
activ
compar
aa
rabbit
fig
rabbit
five
sevenfold
higher
nab
respons
serum
nab
heterolog
boost
aa
anim
comparison
boost
effect
found
aa
rabbit
heterolog
boost
like
determin
extent
secondari
nab
respons
anim
prolong
time
cours
continu
observ
greater
nab
respons
rabbit
prime
mva
boost
addit
measur
week
boost
measur
nab
respons
week
boost
base
extrapol
show
level
nab
rabbit
remain
significantli
greater
long
month
booster
fig
fact
level
initi
rose
fourfold
increas
rabbit
aa
rabbit
week
boost
remain
two
three
time
greater
extend
measur
fig
observ
serum
nab
level
rabbit
show
averag
increas
twofold
day
boost
level
drop
back
observ
upon
prime
fig
aa
rabbit
fail
show
increas
serum
nab
level
prime
rabbit
hand
show
five
sevenfold
increas
aa
rabbit
nab
level
week
boost
sustain
two
threefold
increas
week
therefor
heterolog
mva
prime
boost
shown
immunogen
elicit
prolong
nab
immun
respons
sarscov
emerg
sar
epidem
much
attent
focus
develop
effect
vaccin
combat
threat
recurr
previous
show
promis
use
mva
protect
pathogen
sarscov
challeng
chines
rhesu
monkey
chen
et
al
studi
variou
regimen
mice
rabbit
determin
optim
condit
requir
induc
greatest
longlast
nab
respons
sarscov
begin
mice
prime
nonrepl
compet
initi
highest
level
serum
nab
sarscov
viru
fig
dna
mva
prime
show
significantli
lower
level
nab
induc
primari
nab
respons
howev
predict
effect
prime
boost
mice
either
mva
result
increas
serum
nab
interestingli
increas
level
nab
respons
significantli
lower
mvasprim
mice
fig
find
indic
import
heterolog
mva
prime
boost
regimen
induc
substanti
level
nab
respons
use
regimen
also
offer
advantag
overcom
problem
relat
vaccineinduc
immun
respons
live
viral
vector
similar
find
mice
observ
significantli
lower
level
nab
rabbit
prime
mva
compar
fig
upon
boost
rabbit
either
mva
serum
nab
level
increas
twofold
mvasboost
anim
less
twofold
anim
week
boost
howev
mvasprim
rabbit
reach
significantli
higher
serum
nab
titer
week
boost
suspect
homolog
mva
prime
boost
fail
reach
substanti
level
preexist
immun
prime
probabl
result
expedit
vector
interfer
clearanc
heterolog
vaccin
regimen
underlin
mechan
prime
mva
superior
interest
investig
possibl
mva
much
better
prime
memori
b
cell
essenti
boost
potent
nab
respons
moreov
high
level
nab
respons
gener
prime
necessarili
indic
similar
level
memori
respons
simultan
induc
week
observ
found
significantli
higher
level
two
threefold
serum
titer
serum
nab
mvasprim
rabbit
compar
anim
receiv
regimen
furthermor
nab
measur
base
serum
titer
show
even
appar
dispar
rabbit
show
littl
benefici
effect
homolog
boost
wherea
mvasboost
rabbit
show
rapid
twofold
increas
return
level
observ
prime
mvasprim
rabbit
howev
much
greater
increas
heterolog
boost
persist
two
threefold
higher
level
week
later
clearli
rabbit
prime
mva
boost
show
substanti
advantag
immun
regimen
test
trigger
persist
vaccineinduc
nab
respons
high
qualiti
quest
optim
vaccin
vector
deliveri
system
strategi
subject
often
rais
vaccin
design
data
gener
nonhuman
primat
demonstr
dna
primemva
boost
regimen
superior
either
vaccin
use
alon
induc
high
level
protect
cellmedi
respons
pathogen
simian
immunodefici
viru
siv
humansimian
immunodefici
viru
shiv
amara
et
al
horton
et
al
strategi
also
proven
effect
influenza
malaria
degano
et
al
mcconkey
et
al
similarli
dna
boost
regimen
also
show
great
efficaci
nonhuman
primat
shiv
challeng
shiver
et
al
date
studi
evalu
regimen
use
live
viral
vector
among
boost
adenovirusprim
immun
respons
mva
vaccin
led
enhanc
immunogen
substanti
protect
efficaci
mice
malaria
shiv
infect
casimiro
et
al
gilbert
et
al
fact
mva
primeadenoviru
boost
regimen
score
second
best
studi
induc
protect
immun
gilbert
et
al
demonstr
first
time
heterolog
mva
prime
boost
regimen
offer
great
advantag
induc
nab
sarscov
find
use
studi
aid
vaccin
design
recogn
cellmedi
respons
alon
suffici
achiev
steril
immun
great
interest
determin
whether
regimen
would
improv
immunogen
profil
promis
yet
weak
immunogen
aim
induc
nab
